Exclusive Interview with Organigram CEO Beena Goldenberg Canadian LP Organigram (NASDAQ: OGI) (TSX: OGI) has demonstrated a streak of success in the market as it approaches the end of...
This is a copy of the May 19th edition of our weekly Newsletter, which we have been publishing since October 2015. With 19 conference calls confirmed by the New Cannabis Ventures Earnings...
Exclusive Interview with Hyasynth Co-Founder and CEO Kevin Chen Right now, traditional agricultural practices are the main production method of natural cannabinoids. It takes months to create a final...
Canadian investment bank AltaCorp Capital has published a research report explaining options for producing cannabinoids from sources beyond cannabis. Analyst and Managing Director David Kideckel, PhD, explained in “Synthetically-Derived...
This article was published originally at 420 Investor in October A highly disruptive technology that I have discussed over the past few years appears to be gaining traction. Biosynthesis,...
Organigram invests in Hyasynth Biologicals Inc., helps bring transformative “cellular agriculture” to Canadian cannabis industry Investment solidifies Organigram’s commitment to next generation delivery of cannabinoid products to global medical...
Organigram Announces Letter of Intent for Strategic Investment in Hyasynth Biologicals Inc. Investment in Hyasynth Biologicals Inc. would advance Organigram’s interest in next generation cannabinoids MONCTON, NB, May 24,...
In September, the New York Times reported that THC can be produced from yeast. It turns out that not only THC but many of the cannabinoids as well as terpenes...
The South by Southwest (SXSW) Conference & Festivals, a major gathering in Austin, TX that will celebrate its 30th anniversary this year, is known for allowing attendees to discover the...
